NOVO Nordisk Pharmaceuticals
has initiated a recall for product
correction of certain lots of its
NordiPen device, which is a nonsterile
re-usable injector pen
used with 5mg, 10mg and 15mg
Norditropin SimpleXx (somatropin)
human growth hormone cartridges.
It’s been identified that
some users may have difficulty
assembling the device, due to
a minor design change to the
shape of a component which
could lead to increased resistance
during assembly, causing the user
to assume the pen is correctly
assembled when it is not.
This in turn could lead to the
patient injecting less medicine than
the intended dose.
Novo Nordisk is undertaking
design improvements and will
replace all affected devices once
unaffected stock is available,
expected in Oct 2013.The above article was sent to subscribers in Pharmacy Daily's issue from 24 Jul 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Jul 13
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.